Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Earnings Roundup: Bayer (Part 8)

This article was originally published in PharmAsia News

Executive Summary

Bayer saw 40% of its revenues come from emerging markets in the fourth quarter of 2013. The health care business unit lagged in Asia for the year, but the company expects rapid growth in China through acquisitions and other expansion plans.

You may also be interested in...



Algeta’s Bayer Buyout: Assessing A Rare Case of Partner Acquisition

Few biotechs are acquired by their partners -- only about a half dozen in each of the last two years, making the Bayer acquisition of Algeta an exception to the rule. Like other recent billion-dollar partner acquisitions, expectations for subsequent performance seem high.

Stronger Euro Could Make Bayer’s Full-Year Sales Target “Ambitious”

The German conglomerate highlights sales of its five new medicines that have gotten off to good starts in the marketplace and has identified another five early stage cardiology and oncology products to push through its pipeline.

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC086687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel